Dorien Clarisse

Gent, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A Convenient Laboratory-Scale Synthesis Route Toward the PPARα Agonist Pemafibrate.

A Convenient Laboratory-Scale Synthesis Route Toward the PPARα Agonist Pemafibrate.

Journal: ChemistryOpen

Published: February 19, 2026

Optimizing efficacy to safety ratio of glucocorticoids in rheumatoid arthritis models by leveraging PPARα agonism.

Optimizing efficacy to safety ratio of glucocorticoids in rheumatoid arthritis models by leveraging PPARα agonism.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 22, 2025

Modeling of glucocorticoid resistance in multiple myeloma reveals mechanisms and markers of glucocorticoid resistance.

Modeling of glucocorticoid resistance in multiple myeloma reveals mechanisms and markers of glucocorticoid resistance.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 08, 2025

Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome.

Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome.

Journal: Bioorganic chemistry

Published: December 23, 2024

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.

Journal: Pharmacological research

Published: December 19, 2024

Synthesis and functional screening of novel inhibitors targeting the HDAC6 zinc finger ubiquitin-binding domain.

Synthesis and functional screening of novel inhibitors targeting the HDAC6 zinc finger ubiquitin-binding domain.

Journal: European journal of medicinal chemistry

Published: October 23, 2024

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression.

PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression.

Journal: Metabolism: clinical and experimental

Published: October 15, 2024

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease.

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease.

Journal: npj metabolic health and disease

Published: March 04, 2024

Crosstalk interactions between transcription factors ERRα and PPARα assist PPARα-mediated gene expression.

Crosstalk interactions between transcription factors ERRα and PPARα assist PPARα-mediated gene expression.

Journal: Molecular metabolism

Published: January 15, 2024

Glucocorticoid receptor signaling: intricacies and therapeutic opportunities.

Glucocorticoid receptor signaling: intricacies and therapeutic opportunities.

Journal: Trends in biochemical sciences

Published: October 06, 2023

The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.

The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.

Journal: Journal of medicinal chemistry

Published: June 05, 2023

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Journal: Cellular and molecular life sciences : CMLS

Published: May 22, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026